Your Health, We Care
Most common adverse reactions, including laboratory abnormalities (all Grades, incidence ≥ 20%) were glucose increased, creatinine increased, diarrhea, rash, lymphocyte count decreased, gamma-glutamyl transferase (GGT) increased, nausea, alanine aminotransferase (ALT) increased, fatigue, hemoglobin decreased, lipase increased, decreased appetite, stomatitis, vomiting, weight decreased, calcium decreased, glucose decreased, activated partial thromboplastin time (aPTT) prolonged, and alopecia.
from FDA,2022.11
The purpose of this article is to provide comprehensive guidance for patients and healthcare professionals by providing an in-depth discussion of the side effects of alpelisib, the···【more】
Article source：Lucius LaosRelease date：2024-12-20Recommended：82
Apellix is a drug that targets the PI3Kα pathway, providing a new treatment option for breast cancer patients, but its side effects and coping methods have become the focus of pati···【more】
Article source：Lucius LaosRelease date：2024-12-20Recommended：61
Alpelisib, an innovative targeted therapy drug, brings new hope for specific types of breast cancer patients. However, like many powerful drugs, apellix can be accompanied by a ran···【more】
Article source：Lucius LaosRelease date：2024-12-20Recommended：79
As a PIK3CA kinase inhibitor, Alpelisib plays an important role in the relationship between the activation of the PI3K pathway and tumor drug resistance, especially in patients wit···【more】
Article source：Lucius LaosRelease date：2024-08-27Recommended：139
Alpelisib effectively treats patients with HR/HER2- breast cancer harboring PIK3CA mutations by inhibiting the PI3Kα signaling pathway; The precise targeting effect greatly reduces···【more】
Article source：Lucius LaosRelease date：2024-08-26Recommended：135
As the first PI3Kα inhibitor, Alpelisib has shown significant efficacy in the treatment of HR/HER2- breast cancer. By targeting PIK3CA mutations, drugs can prolong the progression-···【more】
Article source：Lucius LaosRelease date：2024-08-26Recommended：173
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
